New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.

A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.

2017 was a watershed year in many respects, politically, economically and commercially for many players in the medtech field. Where will the opportunities lie in 2018, will breakthrough medtech innovation still have a place among providers often riding on fumes when it comes to budgets, and is it all as bad as some would make out?